- Quantum BioPharma has signed an agreement with a contract development and manufacturing organisation (CDMO) to produce an oral formulation of Lucid-MS for its Phase 2 clinical trial.
- Lucid-MS is a patented, first-in-class neuroprotective compound designed to treat multiple sclerosis by preventing demyelination.
Quantum BioPharma Ltd. has entered into an agreement with a leading contract development and manufacturing organisation (CDMO) to produce an oral formulation of Lucid-MS, the company’s investigational treatment for multiple sclerosis (MS). The oral formulation will be used in a Phase 2 clinical trial to test the drug’s efficacy in restoring mobility in people affected by MS.
Lucid-MS is a patented New Chemical Entity (NCE) and is described as a first-in-class, non-immunomodulatory, neuroprotective compound. According to the company, preclinical models have demonstrated its potential to prevent demyelination, a key characteristic of MS and other neurodegenerative diseases involving damage to the myelin sheath surrounding nerve fibres.
The drug candidate, also known as Lucid-21-302, has been shown in multiple animal studies over the past decade that it may help restore walking ability. The planned Phase 2 trial will be the first to evaluate its effects in humans.
Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma, said: “We are pleased to announce that we have signed this agreement with a leading CDMO to develop and manufacture an oral formulation of Lucid-MS. This marks an important step in the clinical development of Lucid-MS as we prepare the Investigational New Drug (IND) application with the FDA and prepare for our upcoming Phase 2 trial of Lucid-21-302 in MS.”
